Clinical Trial Update: FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

Phase 1 study evaluating FHD-286 in combination with low-dose weekly decitabine and venetoclax in adults with acute myeloid leukemia or myelodysplastic syndrome…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome

Drugs mentioned

• Dacogen (decitabine)
• FHD-286
• Venclexta (venetoclax)

Snippet

Sponsor: Montefiore Medical Center | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: RECRUITING